Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2020

01-12-2020 | Hyperthyroidism | Research article

Predictors of euthyreosis in hyperthyroid patients treated with radioiodine 131I: a retrospective study

Authors: Albert Stachura, Tomasz Gryn, Bernadetta Kałuża, Tadeusz Budlewski, Edward Franek

Published in: BMC Endocrine Disorders | Issue 1/2020

Login to get access

Abstract

Background

Radioiodine (RAI) treatment for hyperthyroidism is a very common modality, chosen by physicians worldwide. The outcome of the therapy, however, is not always predictable. While rendering a patient hypo- or euthyroid is meant as a therapeutic success, the latter does not require lifelong hormonal supplementation. The aim of our study is to determine predictors of euthyreosis in patients who underwent RAI treatment.

Methods

Medical records of 144 patients who had undergone RAI therapy were examined. Laboratory and clinical data were analyzed statistically. Ultrasonography findings, such as thyroid volume, nodules’ size and characteristics had been collected at the beginning of treatment and 6 months after the administration of radioiodine 131I. Moreover, scintigraphy results were taken into account. Multivariate logistic regression analysis model has been used to find predictors of euthyroidism after 12 months of follow-up. The predictors of normal thyroid function have also been analyzed separately for patients with GD (Graves’ disease) and TMNG (toxic multinodular goiter).

Results

The analysis showed that age (OR 1,06; 95%CI 1.025-1.096, p = 0,001), thyroid gland volume (OR 1,04; 95%CI 1,02-1,06; p < 0.001) and iodine uptake level (OR 0,952; 95%CI 0,91-0,98; p = 0,004) were significant factors of achieving normal thyroid function after RAI therapy. According to multivariate logistic regression analysis, in GD patients only age has been shown to be a significant factor (OR 1,06; 95%CI 1,001-1,13; p = 0.047), while in TMNG patients’ age (OR 1,04; 95%CI 1–1,09; p = 0.048), thyroid gland volume (OR 1.038; 95%CI 1.009-1.068; p = 0.009) and iodine uptake level (OR 0.95; 95%CI 0.9–0.99; p = 0.02) all have been proven to be significant predictors of achieving euthyroidism.

Conclusions

The more advanced age, larger volume of thyroid gland and lower iodine uptake level are predictors of euthyreosis after RAI treatment.
Literature
2.
go back to reference Singer PA, Cooper DS, Levy EG, Ladenson PW, Braverman LE, Daniels G, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of care committee, American Thyroid Association. JAMA. 1995;273(10):808–12.CrossRefPubMed Singer PA, Cooper DS, Levy EG, Ladenson PW, Braverman LE, Daniels G, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of care committee, American Thyroid Association. JAMA. 1995;273(10):808–12.CrossRefPubMed
3.
go back to reference Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of graves’ disease. J Clin Endocrinol Metab. 2012;97(12):4549–58.CrossRefPubMed Burch HB, Burman KD, Cooper DS. A 2011 survey of clinical practice patterns in the management of graves’ disease. J Clin Endocrinol Metab. 2012;97(12):4549–58.CrossRefPubMed
4.
go back to reference Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, et al. Differences and similarities in the diagnosis and treatment of graves’ disease in Europe, Japan, and the United States. Thyroid. 1991;1(2):129–35.CrossRefPubMed Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, et al. Differences and similarities in the diagnosis and treatment of graves’ disease in Europe, Japan, and the United States. Thyroid. 1991;1(2):129–35.CrossRefPubMed
6.
go back to reference Wang J, Qin L. Radioiodine therapy versus antithyroid drugs in graves’ disease: a meta-analysis of randomized controlled trials. Br J Radiol. 2016;89(1064):20160418.CrossRefPubMedPubMedCentral Wang J, Qin L. Radioiodine therapy versus antithyroid drugs in graves’ disease: a meta-analysis of randomized controlled trials. Br J Radiol. 2016;89(1064):20160418.CrossRefPubMedPubMedCentral
7.
go back to reference Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–421.CrossRefPubMed Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–421.CrossRefPubMed
8.
go back to reference Weetman AP. Radioiodine treatment for benign thyroid diseases. Clin Endocrinol. 2007;66(6):757–64.CrossRef Weetman AP. Radioiodine treatment for benign thyroid diseases. Clin Endocrinol. 2007;66(6):757–64.CrossRef
9.
go back to reference Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in graves’ hyperthyroidism. J Clin Endocrinol Metab. 2003;88(3):978–83.CrossRefPubMed Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in graves’ hyperthyroidism. J Clin Endocrinol Metab. 2003;88(3):978–83.CrossRefPubMed
10.
go back to reference Jarløv AE, Hegedüs L, Kristensen LO, Nygaard B, Hansen JM. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? Clin Endocrinol. 1995;43(3):325–9.CrossRef Jarløv AE, Hegedüs L, Kristensen LO, Nygaard B, Hansen JM. Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? Clin Endocrinol. 1995;43(3):325–9.CrossRef
11.
go back to reference Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA. Age and gender predict the outcome of treatment for graves’ hyperthyroidism. J Clin Endocrinol Metab. 2000;85(3):1038–42.PubMed Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA. Age and gender predict the outcome of treatment for graves’ hyperthyroidism. J Clin Endocrinol Metab. 2000;85(3):1038–42.PubMed
12.
go back to reference Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab. 2001;86(8):3611–7.PubMed Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine treatment of hyperthyroidism-prognostic factors for outcome. J Clin Endocrinol Metab. 2001;86(8):3611–7.PubMed
13.
go back to reference Catargi B, Leprat F, Guyot M, Valli N, Ducassou D, Tabarin A. Optimized radioiodine therapy of graves’ disease: analysis of the delivered dose and of other possible factors affecting outcome. Eur J Endocrinol. 1999;141(2):117–21.CrossRefPubMed Catargi B, Leprat F, Guyot M, Valli N, Ducassou D, Tabarin A. Optimized radioiodine therapy of graves’ disease: analysis of the delivered dose and of other possible factors affecting outcome. Eur J Endocrinol. 1999;141(2):117–21.CrossRefPubMed
14.
go back to reference Howarth D, et al. Determination of the optimal minimum radioiodine dose in patients with graves’ disease: a clinical outcome study. Eur J Nucl Med. 2001;28:1489–95.CrossRefPubMed Howarth D, et al. Determination of the optimal minimum radioiodine dose in patients with graves’ disease: a clinical outcome study. Eur J Nucl Med. 2001;28:1489–95.CrossRefPubMed
15.
go back to reference Manohar K, Mittal BR, Bhoil A, Bhattacharya A, Dutta P, Bhansali A. Factors predicting treatment failure in patients treated with iodine-131 for graves’ disease. World J Nucl Med. 2013;12(2):57–60.CrossRefPubMedPubMedCentral Manohar K, Mittal BR, Bhoil A, Bhattacharya A, Dutta P, Bhansali A. Factors predicting treatment failure in patients treated with iodine-131 for graves’ disease. World J Nucl Med. 2013;12(2):57–60.CrossRefPubMedPubMedCentral
16.
go back to reference Liu M, Jing D, Hu J, Yin S. Predictive factors of outcomes in personalized radioactive iodine ((131)I) treatment for graves’ disease. Am J Med Sci. 2014;348(4):288–93.CrossRefPubMed Liu M, Jing D, Hu J, Yin S. Predictive factors of outcomes in personalized radioactive iodine ((131)I) treatment for graves’ disease. Am J Med Sci. 2014;348(4):288–93.CrossRefPubMed
17.
go back to reference Zaman MU, Fatima N, Zaman U, Sajjad Z, Zaman A, Tahseen R. Predictive value of pyramidal lobe, percentage thyroid uptake and age for ablation outcome after 15 mCi fixed dose of radioiodine-131 in graves’ disease. Indian J Nucl Med. 2015;30(4):309–13.CrossRefPubMedPubMedCentral Zaman MU, Fatima N, Zaman U, Sajjad Z, Zaman A, Tahseen R. Predictive value of pyramidal lobe, percentage thyroid uptake and age for ablation outcome after 15 mCi fixed dose of radioiodine-131 in graves’ disease. Indian J Nucl Med. 2015;30(4):309–13.CrossRefPubMedPubMedCentral
18.
go back to reference Ceccarelli C, Bencivelli W, Vitti P, Grasso L, Pinchera A. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years’ retrospective study. Clin Endocrinol. 2005;62(3):331–5.CrossRef Ceccarelli C, Bencivelli W, Vitti P, Grasso L, Pinchera A. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years’ retrospective study. Clin Endocrinol. 2005;62(3):331–5.CrossRef
19.
go back to reference Pfeilschifter J, Elser H, Haufe S, Ziegler R, Georgi P. Impact of pretreatment variables on the outcome of standardized 131I therapy with 150 gray in graves’ disease. Nuklearmedizin. 1997;36(3):81–6.CrossRefPubMed Pfeilschifter J, Elser H, Haufe S, Ziegler R, Georgi P. Impact of pretreatment variables on the outcome of standardized 131I therapy with 150 gray in graves’ disease. Nuklearmedizin. 1997;36(3):81–6.CrossRefPubMed
20.
go back to reference Lewis A, Atkinson B, Bell P, Courtney H, McCance D, Mullan K, et al. Outcome of 131I therapy in hyperthyroidism using a 550MBq fixed dose regimen. Ulster Med J. 2013;82(2):85–8.PubMedPubMedCentral Lewis A, Atkinson B, Bell P, Courtney H, McCance D, Mullan K, et al. Outcome of 131I therapy in hyperthyroidism using a 550MBq fixed dose regimen. Ulster Med J. 2013;82(2):85–8.PubMedPubMedCentral
21.
go back to reference Markovic V, Eterovic D. Thyroid echogenicity predicts outcome of radioiodine therapy in patients with graves’ disease. J Clin Endocrinol Metab. 2007;92(9):3547–52.CrossRefPubMed Markovic V, Eterovic D. Thyroid echogenicity predicts outcome of radioiodine therapy in patients with graves’ disease. J Clin Endocrinol Metab. 2007;92(9):3547–52.CrossRefPubMed
22.
go back to reference Blair AL, Lowe DC, Hadden DR, Weaver JA, Montgomery DA. Long term follow up of patients treated for hyperthyroidism with low dose radioactive iodine. Ulster Med J. 1980;49(1):71–8.PubMedPubMedCentral Blair AL, Lowe DC, Hadden DR, Weaver JA, Montgomery DA. Long term follow up of patients treated for hyperthyroidism with low dose radioactive iodine. Ulster Med J. 1980;49(1):71–8.PubMedPubMedCentral
23.
go back to reference Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Radioiodine therapy of graves’ hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Investig. 1995;25(3):186–93.CrossRef Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Radioiodine therapy of graves’ hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Investig. 1995;25(3):186–93.CrossRef
24.
go back to reference Walter MA, Christ-Crain M, Eckard B, Schindler C, Nitzsche EU, Müller-Brand J, et al. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome. Eur J Clin Investig. 2004;34(5):365–70.CrossRef Walter MA, Christ-Crain M, Eckard B, Schindler C, Nitzsche EU, Müller-Brand J, et al. Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome. Eur J Clin Investig. 2004;34(5):365–70.CrossRef
25.
go back to reference Kristoffersen US, Hesse B, Rasmussen AK, Kjaer A. Radioiodine therapy in hyperthyroid disease: poorer outcome in patients with high 24 hours radioiodine uptake. Clin Physiol Funct Imaging. 2006;26(3):167–70.CrossRefPubMed Kristoffersen US, Hesse B, Rasmussen AK, Kjaer A. Radioiodine therapy in hyperthyroid disease: poorer outcome in patients with high 24 hours radioiodine uptake. Clin Physiol Funct Imaging. 2006;26(3):167–70.CrossRefPubMed
26.
go back to reference Tamatea JA, Conaglen JV, Elston MS. Response to radioiodine therapy for thyrotoxicosis: disparate outcomes for an indigenous population. Int J Endocrinol. 2016;2016:7863867.CrossRefPubMedPubMedCentral Tamatea JA, Conaglen JV, Elston MS. Response to radioiodine therapy for thyrotoxicosis: disparate outcomes for an indigenous population. Int J Endocrinol. 2016;2016:7863867.CrossRefPubMedPubMedCentral
27.
go back to reference Schneider DF, Sonderman PE, Jones MF, Ojomo KA, Chen H, Jaume JC, et al. Failure of radioactive iodine in the treatment of hyperthyroidism. Ann Surg Oncol. 2014;21(13):4174–80.CrossRefPubMedPubMedCentral Schneider DF, Sonderman PE, Jones MF, Ojomo KA, Chen H, Jaume JC, et al. Failure of radioactive iodine in the treatment of hyperthyroidism. Ann Surg Oncol. 2014;21(13):4174–80.CrossRefPubMedPubMedCentral
28.
go back to reference Boelaert K, Syed AA, Manji N, Sheppard MC, Holder RL, Gough SC, et al. Prediction of cure and risk of hypothyroidism in patients receiving 131I for hyperthyroidism. Clin Endocrinol. 2009;70(1):129–38.CrossRef Boelaert K, Syed AA, Manji N, Sheppard MC, Holder RL, Gough SC, et al. Prediction of cure and risk of hypothyroidism in patients receiving 131I for hyperthyroidism. Clin Endocrinol. 2009;70(1):129–38.CrossRef
29.
go back to reference Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol. 2004;61(5):641–8.CrossRef Metso S, Jaatinen P, Huhtala H, Luukkaala T, Oksala H, Salmi J. Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol. 2004;61(5):641–8.CrossRef
30.
go back to reference Erem C, Kandemir N, Hacihasanoglu A, Ersöz HO, Ukinc K, Kocak M. Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome. Endocrine. 2004;25(1):55–60.CrossRefPubMed Erem C, Kandemir N, Hacihasanoglu A, Ersöz HO, Ukinc K, Kocak M. Radioiodine treatment of hyperthyroidism: prognostic factors affecting outcome. Endocrine. 2004;25(1):55–60.CrossRefPubMed
31.
go back to reference Knapska-Kucharska M, Oszukowska L, Lewiński A. Analysis of demographic and clinical factors affecting the outcome of radioiodine therapy in patients with hyperthyroidism. Arch Med Sci. 2010;6(4):611–6.CrossRefPubMedPubMedCentral Knapska-Kucharska M, Oszukowska L, Lewiński A. Analysis of demographic and clinical factors affecting the outcome of radioiodine therapy in patients with hyperthyroidism. Arch Med Sci. 2010;6(4):611–6.CrossRefPubMedPubMedCentral
32.
go back to reference Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Treatment of graves’ hyperthyroidism with radioiodine: results of a prospective randomized study. Thyroid. 1997;7(2):247–51.CrossRefPubMed Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Treatment of graves’ hyperthyroidism with radioiodine: results of a prospective randomized study. Thyroid. 1997;7(2):247–51.CrossRefPubMed
33.
go back to reference Alexander EK, Larsen PR. High dose of (131) I therapy for the treatment of hyperthyroidism caused by graves’ disease. J Clin Endocrinol Metab. 2002;87(3):1073–7.PubMed Alexander EK, Larsen PR. High dose of (131) I therapy for the treatment of hyperthyroidism caused by graves’ disease. J Clin Endocrinol Metab. 2002;87(3):1073–7.PubMed
34.
go back to reference Yamashita Y, Yamane K, Tamura T, Okubo M, Kohno N. Onset age is associated with outcome of radioiodine therapy in graves’ disease. Endocr J. 2004;51(2):127–32.CrossRefPubMed Yamashita Y, Yamane K, Tamura T, Okubo M, Kohno N. Onset age is associated with outcome of radioiodine therapy in graves’ disease. Endocr J. 2004;51(2):127–32.CrossRefPubMed
35.
go back to reference Bonnema SJ, Hegedüs L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2012;33(6):920–80.CrossRefPubMed Bonnema SJ, Hegedüs L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2012;33(6):920–80.CrossRefPubMed
36.
go back to reference Reinhardt MJ, Brink I, Joe AY, Von Mallek D, Ezziddin S, Palmedo H, et al. Radioiodine therapy in graves’ disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med Mol Imaging. 2002;29(9):1118–24.CrossRefPubMed Reinhardt MJ, Brink I, Joe AY, Von Mallek D, Ezziddin S, Palmedo H, et al. Radioiodine therapy in graves’ disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med Mol Imaging. 2002;29(9):1118–24.CrossRefPubMed
37.
go back to reference Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic D, et al. Outcome of thyroid function in graves’ patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab. 1998;83(1):40–6.PubMed Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T, Dokic D, et al. Outcome of thyroid function in graves’ patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab. 1998;83(1):40–6.PubMed
38.
go back to reference Jensen BE, Bonnema SJ, Hegedüs L. Glucocorticoids do not influence the effect of radioiodine therapy in graves’ disease. Eur J Endocrinol. 2005;153(1):15–21.CrossRefPubMed Jensen BE, Bonnema SJ, Hegedüs L. Glucocorticoids do not influence the effect of radioiodine therapy in graves’ disease. Eur J Endocrinol. 2005;153(1):15–21.CrossRefPubMed
39.
go back to reference Sabri O, Zimny M, Schulz G, Schreckenberger M, Reinartz P, Willmes K, et al. Success rate of radioiodine therapy in graves’ disease: the influence of thyrostatic medication. J Clin Endocrinol Metab. 1999;84(4):1229–33.PubMed Sabri O, Zimny M, Schulz G, Schreckenberger M, Reinartz P, Willmes K, et al. Success rate of radioiodine therapy in graves’ disease: the influence of thyrostatic medication. J Clin Endocrinol Metab. 1999;84(4):1229–33.PubMed
40.
go back to reference Walter MA, Christ-Crain M, Schindler C, Müller-Brand J, Müller B. Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison. Eur J Nucl Med Mol Imaging. 2006;33(6):730–7.CrossRefPubMed Walter MA, Christ-Crain M, Schindler C, Müller-Brand J, Müller B. Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison. Eur J Nucl Med Mol Imaging. 2006;33(6):730–7.CrossRefPubMed
41.
go back to reference van Isselt JW, de Klerk JM, van Rijk PP, van Gils AP, Polman LJ, Kamphuis C, et al. Comparison of methods for thyroid volume estimation in patients with graves’ disease. Eur J Nucl Med Mol Imaging. 2003;30(4):525–31.CrossRefPubMed van Isselt JW, de Klerk JM, van Rijk PP, van Gils AP, Polman LJ, Kamphuis C, et al. Comparison of methods for thyroid volume estimation in patients with graves’ disease. Eur J Nucl Med Mol Imaging. 2003;30(4):525–31.CrossRefPubMed
42.
go back to reference Jarløv AE, Hegedüs L, Gjørup T, Hansen JE. Accuracy of the clinical assessment of thyroid size. Dan Med Bull. 1991;38(1):87–9.PubMed Jarløv AE, Hegedüs L, Gjørup T, Hansen JE. Accuracy of the clinical assessment of thyroid size. Dan Med Bull. 1991;38(1):87–9.PubMed
44.
go back to reference Nygaard B, Hegedüs L, Ulriksen P, Nielsen KG, Hansen JM. Radioiodine therapy for multinodular toxic goiter. Arch Intern Med. 1999;159(12):1364–8.CrossRefPubMed Nygaard B, Hegedüs L, Ulriksen P, Nielsen KG, Hansen JM. Radioiodine therapy for multinodular toxic goiter. Arch Intern Med. 1999;159(12):1364–8.CrossRefPubMed
45.
go back to reference Kobe C, Eschner W, Wild M, Rahlff I, Sudbrock F, Schmidt M, et al. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I? Nucl Med Commun. 2010;31(3):201–5.CrossRefPubMed Kobe C, Eschner W, Wild M, Rahlff I, Sudbrock F, Schmidt M, et al. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I? Nucl Med Commun. 2010;31(3):201–5.CrossRefPubMed
46.
go back to reference Kobe C, Eschner W, Sudbrock F, Weber I, Marx K, Dietlein M, et al. Graves’ disease and radioiodine therapy: is success of ablation dependent on the achieved dose above 200 Gy? Nuklearmedizin. 2008;47:13–7.CrossRefPubMed Kobe C, Eschner W, Sudbrock F, Weber I, Marx K, Dietlein M, et al. Graves’ disease and radioiodine therapy: is success of ablation dependent on the achieved dose above 200 Gy? Nuklearmedizin. 2008;47:13–7.CrossRefPubMed
Metadata
Title
Predictors of euthyreosis in hyperthyroid patients treated with radioiodine 131I−: a retrospective study
Authors
Albert Stachura
Tomasz Gryn
Bernadetta Kałuża
Tadeusz Budlewski
Edward Franek
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2020
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-020-00551-2

Other articles of this Issue 1/2020

BMC Endocrine Disorders 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.